71% Overall Response Rate for Double vs Single Immunotherapy to Patients with Metastatic Colorectal Cancer
Thierry André, St. Antoine Hospital in Paris, presented at ASCO GI the results of the LBA CheckMate 8HW comparing nivolumab plus ipilimumab vs nivolumab alone for patients with metastatic colorectal cancer. The results were at the day of the presentation at ASCO GI published in the Lancet, showing that the combination of NIVO-IPI have a greater PFS and overall response vs monotherapy with nivolumab.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in